GlaxoSmithKline (GSK) and Theravance’s inhaled lung drug, Relvar, has been approved by Europe’s regulatory body to treat both asthma and chronic obstructive pulmonary disease (COPD). Relvar is a combination of the inhaled corticosteroid fluticasone furoate and the long-acting beta2 agonist (LABA) vilanterol, and is delivered through the Ellipta inhaler. The drug has already been approved
Advisors to the European Medicines Agency (EMA) have voted in support of approving GlaxoSmithKline/ Theravance’s Relvar Ellipta for both asthma and chronic obstructive pulmonary disease (COPD). The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has delivered a response recommending marketing authorisation for Relvar Ellipta, a combination of the inhaled corticosteroid fluticasone
GlaxoSmithKline’s (GSK) Tafinlar has been given the green light by the European Commission to be used as an oral treatment for unresectable or metastatic melanoma in adults with a BRAF V600 mutation. Tafinlar (dabrafenib) is an orally bioavailable inhibitor of BRAF, part of the pathway that regulates the normal growth and death of cells. Mutations
The European Medicines Agency (EMA) has granted GlaxoSmithKline’s (GSK) melanoma drug an accelerated review. The melanoma drug, a MEK inhibitor named trametinib, is requesting a European licence as both a monotherapy and in combination with their investigational BRAF inhibitor dabrafenib, for the medication of patients with unresectable or metastatic melanoma with a BRAF V600 mutation.
GlaxoSmithKline (GSK) has become the first big pharma company to support the AllTrials campaign, which intends to improve clinical trial transparency. The campaign, which is supported by Dr Ben Goldacre, Bad Pharma’s author, and Dr Fiona Godlee, BMJ editor, is pushing for registration of clinical trials and the disclosure of results and reports to help
Aptuit have announced that they have made swift progress in attracting clients to the drug discovery and development centre they acquired from GlaxoSmithKline (GSK) in Verona, Italy as part of a strategic agreement in June 2010. The American founded drug development services organisation now has 100 clients, covering a range of large pharmaceutical multinationals, mid-size
GlaxoSmithKline and Johnson & Johnson (J&J) announced yesterday that they have started Phase III clinical trials of their investigational rheumatoid arthritis (RA) treatment, sirukumab. Johnson & Johnson’s Janssen Biologics unit in Ireland and GlaxoSmithKline have begun a Phase III development programme for sirukumab (otherwise known as CNTO 136), a human anti-interleukin (IL)-6 monoclonal antibody. The
The anti-doping facilities presently operated by King’s College London at the Harlow research site of GSK (GlaxoSmithKline), official test centre service provider for the London 2012 Olympic and Paralympics Games, will be transformed once the Games have finished into a centre for investigating phenome patterns to support greater personalised drug development. A phenome describes a
GlaxoSmithKline (GSK) has prolonged their proposition to acquire Human Genome Sciences (HGS) without increasing their $2.60 billion offer, after barely any shares were offered. The UK drugs giant has delayed the expiration date to June 29th for their unsolicited tender offer to acquire all the remaining common shares of Human Genome Sciences at $13.00 each.
GlaxoSmithKline (GSK) wants to change the whole board of Human Genome Sciences (HGS), according to a Reuters report, and contenders from across the sector have been approached. The news agency, states that GSK will pursue the assistance from Human Genome Sciences shareholders to exchange the board with 12 independent directors. They claim that the UK